<DOC>
	<DOC>NCT00910429</DOC>
	<brief_summary>Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.</brief_summary>
	<brief_title>BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1 Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY632521 are not allowed to participate in the extension trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic thromboembolic Hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>soluble Guanylate Cyclase Stimulator</keyword>
	<keyword>sGC</keyword>
</DOC>